Share Price | 180 Life Sciences Corp. Stock Analysis & Recommendation

Q: What does 180 Life Sciences Corp. do?

Overview:180 Life Sciences Corp. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:- Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025)- Market cap: USD 5.29 Million (Micro Cap)Key Metrics:- P/E: NA (Loss Making)- Industry P/E: NA- Dividend Yield: 0.00%- Debt Equity: -0.46- Return on Equity: -42.26%- Price to Book: 0.69Contact Details:Details: No Company Details AvailableRegistrar Address: Not available.

Q: Is 180 Life Sciences Corp. technically bullish or bearish?

As of 28 August 2025, the technical trend for 180 Life Sciences Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages and a bullish KST on the weekly timeframe. However, the weekly MACD is mildly bearish, and the monthly RSI indicates bearish momentum. The Bollinger Bands are mildly bullish on both weekly and monthly charts, suggesting some upward potential. In terms of performance, the stock has returned 4.15% over the past week compared to the S&P 500's 1.05%, but it has seen a significant decline of 66.13% over the past month against the S&P's 2.33%. Year-to-date, the stock is up 37.91%, outperforming the S&P 500's 12.22%. Overall, while there are some bullish indicators, the mixed signals suggest caution.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

160.35 k

Shareholding (Sep 2025)

FII

0.32%

Held by 12 FIIs

DII

95.92%

Held by 3 DIIs

Promoter

1.33%

How big is 180 Life Sciences Corp.?

22-Jun-2025

As of Jun 18, 180 Life Sciences Corp. has a market capitalization of 5.29 million, with net sales of 0.00 million and a net profit of -7.47 million. Shareholder's funds were 9.25 million, and total assets amounted to 33.51 million.

View full answer

What does 180 Life Sciences Corp. do?

22-Jun-2025

180 Life Sciences Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $2 million and a market cap of $5.29 million. Key metrics include a negative P/E ratio, no dividend yield, and a price-to-book ratio of 0.69.

View full answer

Is 180 Life Sciences Corp. technically bullish or bearish?

20-Sep-2025

As of August 28, 2025, 180 Life Sciences Corp. shows a mildly bullish trend with mixed signals, having gained 4.15% over the past week but down 66.13% in the last month, while year-to-date it is up 37.91%, outperforming the S&P 500's 12.22%.

View full answer

Compare 180 Life Sciences Corp. with Similar Stocks

Plus Therapeutics, Inc.Panbela Therapeutics, Inc.ABVC BioPharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -1.00% and Operating profit at -329.35% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -6.60

The company has declared negative results in Mar'2025 after 5 consecutive positive quarters

Risky - Negative EBITDA

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 96 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.03

Return on Equity

-50.58%

Price to Book

0.22

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Sep 2025)

Net Profit:

-209 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

207.96%

6 Months

60.37%

1 Year

127.45%

2 Years

-84.86%

3 Years

-99.42%

4 Years

-99.91%

5 Years

-99.92%

180 Life Sciences Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-1.00%

EBIT Growth (5y)

-329.35%

EBIT to Interest (avg)

-6.60

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.46

Sales to Capital Employed (avg)

0.01

Tax Ratio

4.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

24.15%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.77

EV to EBIT

-0.37

EV to EBITDA

-0.38

EV to Capital Employed

0.57

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-153.04%

ROE (Latest)

-42.26%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

Bullish

Bearish

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (2.43%)

Foreign Institutions

Held by 12 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -41,640.00% vs 95.15% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-220.50",
          "val2": "-0.60",
          "chgp": "-36,650.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "11.20",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-208.70",
          "val2": "-0.50",
          "chgp": "-41,640.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-53,646.10%",
          "val2": "0.00%",
          "chgp": "-5,364.61%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 68.84% vs 48.58% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-6.30",
          "val2": "-13.40",
          "chgp": "52.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.90",
          "val2": "-8.80",
          "chgp": "67.05%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-19.90",
          "chgp": "68.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

4.10

0.00

Operating Profit (PBDIT) excl Other Income

-220.50

-0.60

-36,650.00%

Interest

0.30

0.00

Exceptional Items

11.20

-0.00

Consolidate Net Profit

-208.70

-0.50

-41,640.00%

Operating Profit Margin (Excl OI)

-53,646.10%

0.00%

-5,364.61%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -41,640.00% vs 95.15% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-6.30

-13.40

52.99%

Interest

0.10

0.00

Exceptional Items

-2.90

-8.80

67.05%

Consolidate Net Profit

-6.20

-19.90

68.84%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 68.84% vs 48.58% in Dec 2023

All Annual Results

Company CV

About 180 Life Sciences Corp.

180 Life Sciences Corp.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

180 Life Sciences Corp.

1Day

52 Week

CASH

FII

DII

Promoter

How big is 180 Life Sciences Corp.?

Watch in Real-Time

What does 180 Life Sciences Corp. do?

Is 180 Life Sciences Corp. technically bullish or bearish?

Compare 180 Life Sciences Corp. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

With a Operating Losses, the company has a Weak Long Term Fundamental Strength

The company has declared negative results in Mar'2025 after 5 consecutive positive quarters

Risky - Negative EBITDA

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About 180 Life Sciences Corp.

Company Coordinates